Edgestream Partners L.P. Acquires New Holdings in Qiagen N.V. (NYSE:QGEN)

Edgestream Partners L.P. acquired a new position in shares of Qiagen N.V. (NYSE:QGEN - Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 75,432 shares of the company's stock, valued at approximately $3,029,000.

Several other hedge funds have also recently made changes to their positions in QGEN. Envestnet Portfolio Solutions Inc. raised its holdings in Qiagen by 3.6% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 9,816 shares of the company's stock worth $438,000 after purchasing an additional 341 shares during the period. Pitcairn Co. raised its position in Qiagen by 5.3% during the fourth quarter. Pitcairn Co. now owns 6,996 shares of the company's stock worth $312,000 after acquiring an additional 354 shares during the period. Exchange Traded Concepts LLC grew its position in shares of Qiagen by 2.3% in the first quarter. Exchange Traded Concepts LLC now owns 17,825 shares of the company's stock valued at $716,000 after purchasing an additional 395 shares during the period. Headlands Technologies LLC increased its stake in shares of Qiagen by 2.0% during the fourth quarter. Headlands Technologies LLC now owns 19,823 shares of the company's stock worth $883,000 after purchasing an additional 397 shares in the last quarter. Finally, LPL Financial LLC raised its position in shares of Qiagen by 2.6% during the 4th quarter. LPL Financial LLC now owns 17,240 shares of the company's stock worth $768,000 after purchasing an additional 432 shares during the last quarter. 70.00% of the stock is owned by institutional investors and hedge funds.

Qiagen Stock Up 0.2%

Shares of NYSE QGEN traded up $0.11 during midday trading on Friday, hitting $48.35. 2,726,997 shares of the company's stock were exchanged, compared to its average volume of 1,224,863. The firm's fifty day simple moving average is $45.95 and its 200-day simple moving average is $42.98. The company has a market cap of $10.75 billion, a PE ratio of 121.23, a P/E/G ratio of 2.46 and a beta of 0.68. Qiagen N.V. has a twelve month low of $37.63 and a twelve month high of $49.30. The company has a debt-to-equity ratio of 0.40, a current ratio of 3.37 and a quick ratio of 2.83.

Qiagen (NYSE:QGEN - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 earnings per share for the quarter, beating analysts' consensus estimates of $0.50 by $0.05. The firm had revenue of $483.46 million during the quarter, compared to analysts' expectations of $465.66 million. Qiagen had a net margin of 4.68% and a return on equity of 14.61%. Qiagen's quarterly revenue was up 5.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.44 earnings per share. Research analysts predict that Qiagen N.V. will post 2.26 EPS for the current fiscal year.

Qiagen Dividend Announcement

The business also recently disclosed a dividend, which was paid on Thursday, July 10th. Shareholders of record on Thursday, July 3rd were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Wednesday, July 2nd. This represents a yield of 0.52%. Qiagen's payout ratio is 62.50%.

Wall Street Analyst Weigh In

QGEN has been the subject of a number of recent research reports. Redburn Atlantic cut shares of Qiagen from a "buy" rating to a "neutral" rating in a research report on Friday, April 4th. Robert W. Baird boosted their price objective on Qiagen from $42.00 to $43.00 and gave the stock a "neutral" rating in a research note on Monday, April 21st. Bank of America boosted their price target on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a research report on Thursday, June 26th. Wall Street Zen raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday, May 15th. Finally, Barclays assumed coverage on Qiagen in a research report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 price objective for the company. Seven equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $49.40.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.